StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.40−0.41 (-7.06%)

Close on Nov 17, 2026Market cap $413.20MP/E –Yield –

Candel Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Candel Therapeutics's profit margin for the twelve months ending Dec 31, 2022 was -15035.2%. For fiscal 2022 it was -15035.2%, against -28899.2% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2022Dec 31, 2022-15035.2%+13864.0
FY2021Dec 31, 2021-28899.2%−14755.2
FY2020Dec 31, 2020-14144.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2022Dec 31, 2022-16396.8%−21545.2
Q3 FY2022Sep 30, 2022-28025.8%+24109.7
Q2 FY2022Jun 30, 2022-13383.9%+41712.9
Q1 FY2022Mar 31, 2022-2819.4%+11625.8
Q4 FY2021Dec 31, 20215148.4%+38948.4
Q3 FY2021Sep 30, 2021-52135.5%−43896.8
Q2 FY2021Jun 30, 2021-55096.8%−45819.4
Q1 FY2021Mar 31, 2021-14445.2%–
Q4 FY2020Dec 31, 2020-33800.0%–
Q3 FY2020Sep 30, 2020-8238.7%–
Q2 FY2020Jun 30, 2020-9277.4%–

More Candel Therapeutics figures

See a number that looks wrong?